Identification of targeted therapy for an aggressive subgroup of muscle-invasive bladder cancers.
Rebouissou et al. recently provided preclinical evidence that a subset of patients with muscle-invasive bladder cancer might benefit from anti-epidermal growth factor receptor (EGFR) therapy and reported diagnostic tools for identifying these patients in the clinical setting. This work also identified relevant experimental models that may be useful for future basic and clinical research on this subgroup of tumors.
Service d'Urologie; Hôpital Foch; Suresnes, France; Université de Versailles; Saint-Quentin-en-Yvelines; Faculté de Médecine Paris; Ile-de-France Ouest; Guyancourt, France.
Thierry
T
Lebret
Service d'Urologie; Hôpital Foch; Suresnes, France; Université de Versailles; Saint-Quentin-en-Yvelines; Faculté de Médecine Paris; Ile-de-France Ouest; Guyancourt, France.
Yann
Y
Neuzillet
Départment d'Oncologie Médicale; Center Hospitalier Régional Universitaire de Nîmes ; Nîmes, France.
Nadine
N
Houede
CNRS; UMR 144; Institut Curie; Paris, France; Institut Curie; Center de Recherche; Paris, France.
Sandra
S
Rebouissou
CNRS; UMR 144; Institut Curie; Paris, France; Institut Curie; Center de Recherche; Paris, France.
Isabelle
I
Bernard-Pierrot
Ligue Nationale Contre le Cancer; Cartes d'Identité des Tumeurs Program ; Paris, France.
Aurélien
A
De Reynies
CNRS; UMR 8200; Institut de Cancérologie Gustave Roussy; Villejuif, France; INSERM; U946; Paris, France.
Simone
S
Benhamou
AP-HP; Hôpitaux Universitaires Henri Mondor; Département de Pathologie; Créteil, France; INSERM; Unité 955; Créteil, France; Université Paris-Est; Faculté de Médecine; Créteil, France; AP-HP; Hôpitaux Universitaires Henri Mondor; Plateforme de Ressources Biologiques; Créteil, France.
Yves
Y
Allory
CNRS; UMR 144; Institut Curie; Paris, France; Institut Curie; Center de Recherche; Paris, France.
François
F
Radvanyi
EGFR; TP53; basal like; bladder carcinoma; epithelial basal cell gene; muscle invasive bladder cancer; retinoblastoma